...
首页> 外文期刊>Frontiers in Pediatrics >Enteroadsorbent Polymethylsiloxane Polyhydrate vs. Probiotic Lactobacillus reuteri DSM 17938 in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers, a Randomized Controlled Trial
【24h】

Enteroadsorbent Polymethylsiloxane Polyhydrate vs. Probiotic Lactobacillus reuteri DSM 17938 in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers, a Randomized Controlled Trial

机译:肠吸收剂聚甲基硅氧烷多水合物与益生菌乳酸杆菌Reuteri DSM 17938在治疗婴儿和幼儿的旋转毒性胃肠炎,随机对照试验

获取原文
           

摘要

Purpose: The aim of this study was to compare two adjunct therapies in the treatment of childhood rotavirus gastroenteritis (RVGE). We compared the recommended treatment, probiotic Lactobacillus reuteri DSM 17938 (BioGaia?), vs. a novel treatment, enterosorbent polymethylsiloxane polyhydrate (Enterosgel?). Methods: This was an open-label, randomized, clinical controlled trial at the University Hospital for Infectious Diseases (UHID) in Zagreb, Croatia. A total of 149 children aged 6–36 months with acute rotaviral gastroenteritis over a period of 48 h, with no significant chronic comorbidity, were randomized to receive the standard therapy with L. reuteri DSM 17938 (hereafter L. reuteri ) or polymethylsiloxane polyhydrate (hereafter PMSPH) therapy, during 5 days. The primary end point was time to recovery in days in both groups. The recovery was defined as absence of fever and vomiting and either the first firm stool, absence of stool for more than 24 h, or return of usual bowel habit. Results: A total of 75 children were randomized into the L. reuteri group and 74 were randomized into the PMSPH group; after excluding missing data, the data from 65 children in each group were analyzed. There was no significant difference in the treatment efficacy between the two regimens with an estimated median time of recovery of 6 days in both groups ( p = 0.754). No significant side effects were observed in either group. Conclusion: Novel enterosorbent PMSPH had a similar efficacy to probiotic L. reuteri in the treatment of rotaviral gastroenteritis in preschool children. Clinical Trial Registration: ClinicalTrials.gov Identifier: {"type":"clinical-trial","attrs":{"text":"NCT04116307","term_id":"NCT04116307"}} NCT04116307 [October 3, 2019] (retrospectively registered). https://clinicaltrials.gov/show/ {"type":"clinical-trial","attrs":{"text":"NCT04116307","term_id":"NCT04116307"}} NCT04116307 .
机译:目的:本研究的目的是比较治疗儿童轮状病毒胃肠炎(RVGE)的两种辅助疗法。我们比较了推荐的治疗,益生菌乳酸杆菌Reuteri dsm 17938(沼气?),与新的处理,肠伞聚甲基硅氧烷多水合物(肠溶液α)。方法:这是克罗地亚萨格勒布传染病(Uhid)大学医院的开放标签,随机,临床对照试验。共有149例6-36个月的儿童,急性旋转性胃肠炎在&lt中的一段时间内,没有明显的慢性合并症,随机地被随机接受L. Reuteri DSM 17938(以下L. Reuteri)或聚甲基硅氧烷的标准治疗。在5天内,多水合物(下文PMSPH)疗法。主要终点是在两组的日子中恢复的时间。恢复被定义为没有发烧和呕吐的缺乏,并且第一件牢固的粪便,粪便超过24小时,或返回通常的排便习惯。结果:将75名儿童随机分配到L. Reuteri组中,74个被随机分为PMSPH组;在排除缺失数据后,分析了每组65名儿童的数据。两种方案之间的治疗效果没有显着差异,估计在两组中恢复6天的估计时间(p = 0.754)。在任一组中没有观察到显着的副作用。结论:新型肠球菌PMSPH在学龄前儿童治疗轮辐胃肠炎的益生菌L. REUTERI类似的疗效。临床试验登记:ClinicalTrials.gov标识符:{“类型”:“临床 - 试验”,“attrs”:{“text”:“nct04116307”,“term_id”:“nct04116307”} n} n:nct04116307 [2019年10月3日](回顾性地注册)。 https://clinicaltrials.gov/show/ {“type”:“临床 - 试验”,“attrs”:{“text”:“nct04116307”,“term_id”:“nct04116307”}} nct04116307。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号